An observational study in Pseudomonas, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by University Hospital, Strasbourg, France · Observational
Among 23 studies in Pseudomonas Infections with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Pseudomonas Infections · France.
Among the 23 studies in Pseudomonas Infections with a site in France, this one is the only one that started in 2023, is one of 5 observational ones, and was the 19th registered.
136 studies on the registry are indexed under Pseudomonas Infections; 27 are open to participants now.
Browse Pseudomonas Infections studies →6 of the 23 studies in Pseudomonas Infections with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier de Saint-Denis · Sites in France
Centre Hospitalier Régional d'Orléans · Sites in France, Réunion
University Hospital, Grenoble · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Pseudomonas Infections studies recruiting now, 11 (55%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 500 is above the median of 100 across 38 observational studies indexed under Pseudomonas Infections.
Median enrollment 113 across the 18 interventional studies, 300 across the 5 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
University Hospital, Strasbourg, France has 1 study filed under Pseudomonas Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Pseudomonas Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT06738771Centre Hospitalier Régional d'OrléansAntimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa | 2027-01 |
Among the 23 studies in Pseudomonas Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity.
This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made "at standard dose") in Pseudomonas infections sensitive to other beta-lactams.
In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam ("restricted" antibiogram).
The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.
Major subject (≥18 years old) with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of Meropenem prescriptions in Pseudomonas spp bacteraemia susceptible to narrow-spectrum betalactams
This study is retrospective, the analysis focuses on the medical records of patients treated at the Strasbourg University Hospital between June 1, 2018 and November 30, 2022.
Time frame: Files analysed retrospectively from June 1, 2018 to November 30, 2022 will be examined
Started Mar 2023 (actual). Primary completion is estimated for Mar 2024, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →